Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search

Invention Type

Information Technology/Software
Medical Device
Research Tool

Research Area

Allergy/Respiratory/Pulmonary Disease
Degenerative Disease
Genetic Disease
Health Care Management
Infectious Disease
Internal Medicine
Metabolic Disease
Personalized Medicine
Psychiatric Disease
Regenerative Medicine
Stem Cell
Surgery/Wound Healing
CMCC 1199

Novel Fluorine-18 Labeled Rhodamine Derivatives For Myocardial Perfusion Imaging With Positron Emission Tomography

Inventors: Alan Packard, Carmen Solorzano, S. Treves, Tobias Heinrich

Invention Types: Diagnostic/Prognostic, Research Tool

Research Areas: Cardiovascular/Cardiology, Radiology

Keywords: Composition of Matter, Reagent, Small Molecule/Drug

For More Information Contact:  Herrera Gutierrez, Aida


Invention Description:

The inventors describe novel fluorine-18 labeled rhodamine derivatives for use in PET for diagnostic evaluation of myocardial perfusion. Myocardial perfusion imaging provides functional imaging for the diagnosis and assessment of ischemic heart disease. Damaged myocardium receives lower blood perfusion than the unaffected tissues and can be imaged with radiocompounds that target the myocardial tissue. Radiologic imaging in cardiac stress tests is preferential to echocardiography, with higher specificity and sensitivity of diagnosis and better ability to localize affected regions. Most nuclear cardiac stress tests use Tc99m-labeled imaging reagents and detection by single photon emission computed tomography (SPECT) imaging. Positron emission tomography (PET)-based myocardial perfusion imaging provides functional images of high quality that can be co-registered with images of metabolic activity.


Myocardial perfusion imaging is useful in the diagnosis of cardiac disease. PET-based myocardial perfusion imaging provides functional images of high quality that can be co-registered with [18F] fluoro-deoxy-glucose images to delineate regions of infarct and ischemia.

Competitive Advantages:

Short-lived compounds such as [15O]H2O, [13N]NH3, and 82Rb are well established myocardial perfusion imaging tracers; however, there are challenges to the production and distribution of these compounds. For example, PET centers without a cyclotron are limited to using 82Rb, which has significant limitations including high cost and high positron energy. The development of an 18F myocardial perfusion tracer that could be distributed from central radiopharmacies would obviate these limitations. The one-pot labeling procedure described in this invention is fast (the two steps require only 45 min.) and provides a high overall yield (35-6%). The radiochemical purity after solid phase extraction is greater than 90%.

Business Opportunity:

Exclusive license

Key Publications: Heinrich TK, Gottumukkala V, Snay E, et al. Synthesis of of fluorine-18 labeled rhodamine B: A potential PET myocardial perfusion imaging agent. Appl Radiat Isot. 2010 Jan;68(1):96-100.

Gottumukkala V, Heinrich TK, Baker A, et al. Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent. Nucl Med Biol. 2010 Apr;37(3):365-70.

Bartholomàˆ MD, Zhang S, Akurathi V, et al. (18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines. Nucl Med Biol. 2015 Oct;42(10):796-803.

IPStatus: Patented